Form 4 for RMD ResMed|
Accepted 2023-10-17 00:00:00 ET · period of report 2023-10-16 · accession 0001127602-23-026027 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-17 | 2023-10-16 | RMD | Farrell Michael J. | CEO | S - Sale+OE | $140.70 | -5,675 | 449.4K | -1% | -$798.5K |
| D | 2023-10-17 | 2023-10-16 | RMD | Farrell Michael J. | CEO | M - OptEx | $57.76 | +5,675 | 455.0K | +1% | +$327.8K |
| D | 2023-10-17 | 2023-10-16 | RMD | Farrell Michael J. | CEO | M - OptEx | $0.00 | -5,675 | 9,140 | -38% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | ResMed Common Stock | 2023-10-16 | S | D | 5,675 | $140.70 | 449,360 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $139.745 to 141.56. The price reported above reflects the weighted average sale price. |
| 2 | Common | ResMed Common Stock | 2023-10-16 | M | A | 5,675 | $57.76 | 455,035 | D | — | — | |
| 3 | Derivative | ResMed Common Stock Options | 2023-10-16 | M | D | 5,675 | $0.00 | 9,140 | D | $57.76 · 2017-11-11 to 2023-11-16 | 5,675 ResMed Common Stock | (F3) Options are exercisable 1/3 each year beginning 1 year from date of grant. |